Literature DB >> 23526377

(18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings.

Tao Huang1, A Cahid Civelek, Huaiyu Zheng, Chin K Ng, Xiaoxian Duan, Junling Li, Gregory C Postel, Baozhong Shen, Xiao-Feng Li.   

Abstract

The objective of this study was to determine whether (18)F-misonidazole could detect hypoxia in macroscopic and microscopic tumors in mice. In nude mice, subcutaneous xenografts and peritoneal metastases were generated utilizing human non-small cell lung cancer A549 and HTB177 cells. Animals were co-injected with (18)F-misonidazole, pimonidazole and bromodeoxyuridine, and tumor perfusion was assessed by Hoechst 33342 injection. The intratumoral distribution of (18)F-misonidazole was determined by micro-PET scan and autoradiography. Pimonidazole, bromodeoxyuridine and Hoechst 33342 were detected by immunohistochemistry on the autoradiography sections. Submillimeter micrometastases found to be severely hypoxic. In both peritoneal metastases and subcutaneous xenografts models, PET images displayed significant (18)F-misonidazole uptake, and its distribution was non-uniform in these macroscopic subcutaneous tumors. In frozen sections, digital autoradiography and immunohistochemistry revealed similar distributions of (18)F-misonidazole, pimonidazole and glucose transporter-1, in both microscopic and macroscopic tumors. Bromodeoxyuridine stained-positive proliferative regions were well perfused, as judged by Hoechst 33342, and displayed low (18)F-misonidazole accumulation. (18)F-misonidazole uptake was low in tumor stroma and necrotic zones as well. Microscopic non-small cell lung cancer metastases are severely hypoxic. (18)F-misonidazole PET is capable to image hypoxia noninvasively not only in macroscopic tumors but also in micrometastases growing in mice. Accordingly, (18)F-misonidazole may be a promising agent to detect the burden of micrometastatic diseases.

Entities:  

Keywords:  18F-misonidazole; Micrometastasis; PET; autoradiography; hypoxia

Year:  2013        PMID: 23526377      PMCID: PMC3601474     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  27 in total

1.  Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Authors:  Amy L Vāvere; Jason S Lewis
Journal:  Dalton Trans       Date:  2007-09-25       Impact factor: 4.390

Review 2.  Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

Authors:  Yu Yang Soon; Martin R Stockler; Lisa M Askie; Michael J Boyer
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.

Authors:  Xiao-Feng Li; Yuanyuan Ma; Xiaorong Sun; John L Humm; C Clifton Ling; Joseph A O'Donoghue
Journal:  J Nucl Med       Date:  2010-04       Impact factor: 10.057

4.  Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.

Authors:  Pierre Vera; Pierre Bohn; Agathe Edet-Sanson; Alice Salles; Sebastien Hapdey; Isabelle Gardin; Jean-François Ménard; Romain Modzelewski; Luc Thiberville; Bernard Dubray
Journal:  Radiother Oncol       Date:  2010-11-04       Impact factor: 6.280

5.  Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.

Authors:  Tao Huang; A Cahid Civelek; Junling Li; Huijie Jiang; Chin K Ng; Gregory C Postel; Baozhong Shen; Xiao-Feng Li
Journal:  J Nucl Med       Date:  2012-06-19       Impact factor: 10.057

Review 6.  Hypoxia in microscopic tumors.

Authors:  Xiao-Feng Li; Joseph A O'Donoghue
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

7.  Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.

Authors:  Xiao-Feng Li; Xiaorong Sun; Yuanyuan Ma; Makiko Suehiro; Mutian Zhang; James Russell; John L Humm; C Clifton Ling; Joseph A O'Donoghue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-17       Impact factor: 9.236

8.  Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.

Authors:  Esther G C Troost; Peter Laverman; Mariëlle E P Philippens; Jasper Lok; Albert J van der Kogel; Wim J G Oyen; Otto C Boerman; Johannes H A M Kaanders; Johan Bussink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-18       Impact factor: 9.236

9.  Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET.

Authors:  Christopher C Riedl; Peter Brader; Pat B Zanzonico; Yun Shin Chun; Yanghee Woo; Paramjeet Singh; Sean Carlin; Bixiu Wen; C Clifton Ling; Hedvig Hricak; Yuman Fong
Journal:  Radiology       Date:  2008-08       Impact factor: 11.105

10.  The histological structure of some human lung cancers and the possible implications for radiotherapy.

Authors:  R H THOMLINSON; L H GRAY
Journal:  Br J Cancer       Date:  1955-12       Impact factor: 7.640

View more
  13 in total

Review 1.  Systematic imaging in medicine: a comprehensive review.

Authors:  Kai Zhang; Yujie Sun; Shuang Wu; Min Zhou; Xiaohui Zhang; Rui Zhou; Tingting Zhang; Yuanxue Gao; Ting Chen; Yao Chen; Xin Yao; Yasuyoshi Watanabe; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-19       Impact factor: 9.236

Review 2.  Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?

Authors:  Jianbo Li; Guojian Zhang; Xuemei Wang; Xiao-Feng Li
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

3.  Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.

Authors:  Pei-Hsin Cheng; Xiao-Mei Rao; Xiaoxian Duan; Xiao-Feng Li; Michael E Egger; Kelly M McMasters; H Sam Zhou
Journal:  J Mol Med (Berl)       Date:  2014-11-08       Impact factor: 4.599

Review 4.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology.

Authors:  Pamela Mena-Romano; Caixia Cheng; Christin Glowa; Peter Peschke; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss; Christian P Karger
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

Review 6.  Transpathology: molecular imaging-based pathology.

Authors:  Mei Tian; Xuexin He; Chentao Jin; Xiao He; Shuang Wu; Rui Zhou; Xiaohui Zhang; Kai Zhang; Weizhong Gu; Jing Wang; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

7.  Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice.

Authors:  Pei-Hsin Cheng; Xiao-Mei Rao; Stephen L Wechman; Xiao-Feng Li; Kelly M McMasters; Heshan Sam Zhou
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

8.  Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.

Authors:  Baozhong Shen; Tao Huang; Yingying Sun; Zhongnan Jin; Xiao-Feng Li
Journal:  Oncotarget       Date:  2017-06-27

9.  (18)F-fluorodeoxyglucose uptake and tumor hypoxia: revisit (18)f-fluorodeoxyglucose in oncology application.

Authors:  Xiao-Feng Li; Yang Du; Yuanyuan Ma; Gregory C Postel; A Cahid Civelek
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

Review 10.  18F-Fluoromisonidazole in tumor hypoxia imaging.

Authors:  Zuoyu Xu; Xiao-Feng Li; Hongyan Zou; Xilin Sun; Baozhong Shen
Journal:  Oncotarget       Date:  2017-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.